Lately, SP-8365—a new inhibitor of the complex CyPA/EMMPRIN—was found effective for the treatment of atherosclerosis by reducing plaque progression and stabilizing vulnerable plaque in apoE-deficient mice [28]. Here, BSG is linked to atherosclerosis.